Is It Time To Buy For Pfizer Stock?

 

Pfizer

Pfizer stated in its 4th quarter update that it expects sales of the COVID-19 vaccine BNT162b2 to reach $ 15 billion throughout the year. However, as the company has received a lot of additional orders since then, the actual total will likely be well above this level. Pfizer will share the vaccine's profits with its partner BioNTech, but mega-drug maker is still poised to enjoy an enormous top and bottom line growth thanks to BNT162b2 . The good news is that Pfizer was in a position to maintain solid growth even without the COVID-19 vaccine. In November, Pfizer merged Upjohn and Mylan to form Viatris. As a result, Pfizer no longer has a number of older drugs that are out of date and suppress growth.

The company predicts an adjusted earnings per share increase of at least 6 percent and an adjusted earnings per share increase of at least 10 percent over the next few years, with the exception of any impact from the COVID-19 vaccine.

In addition to BNT162b2 (Covid-19 vaccine), Pfizer also has multiple growth factors. Sales of the blood thinner Eliquis, cancer drugs Ibrance, Xtandi and Vyndaqel for rare heart disease continue to increase. The company's portfolio of biosimilars (similar versions of original biotech products produced after the patent expires) is also gaining momentum. More than 30 of Pfizer's close to 95 clinical programs are either awaiting regulatory approval or are in end-stage testing.

Almost every investor will like Pfizer's dividend rate. Dividend yield is currently at 4.4 percent.

Despite robust growth prospects and large dividends, large pharmaceutical stock remains relatively bargain. Stocks are now traded less than 11 times the expected earnings.   Is It Time To Buy For Pfizer Stock? Source: https://www.fool.com/ You may also be interested in:

Stocks That Can Double Your Money – Pinterest